To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.
Promotion in emerging markets offers several very important benefits to pharmaceutical companies:
Jay Carter
However, it is a flawed assumption to believe that growing a marketing presence in emerging markets automatically requires a global agency network.
Savvy global marketers should consider other options carefully. Here are four reasons why:
1. If the market you are entering is truly emerging, there is likely to be uneven quality among local agencies. It may sound appealing to hear a network executive claim uniform excellence. However, if there is even a 75 percent chance that the network you contract with has the best agency for a client's brand in a specific market (a spectacularly generous assumption), then the chances that six countries will all have the best agency with a single network is a whopping 18 percent. Simple statistics dictate that a global leader allow—even encourage—each affiliate to choose the agency that is the best fit locally.
2. As you build local affiliates, hire and develop independent leaders for them. This is an imperative for all of the organizations I work with on a daily basis. Taking away the ability of the affiliate general managers to select their own agencies reduces their ability to truly adapt to local needs.
3. The cost savings often cited by networks are based upon reducing the cost of creating six different campaigns, and not upon reducing local affiliate labor costs; each affiliate will still need to execute tactics locally.
4. For all these reasons, AbelsonTaylor advocates a simple brand book process: the pharmaceutical company's global marketing organization (often in partnership with the US affiliate, due to its dominant size) collaborates on the necessary insight work and brand development to create a global brand.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.